Research programme: anti-cancer and anti-inflammatory biosimilars - Amgen/Simcere Pharmaceutical

Drug Profile

Research programme: anti-cancer and anti-inflammatory biosimilars - Amgen/Simcere Pharmaceutical

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Simcere Pharmaceutical Group
  • Class Anti-inflammatories; Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 26 Sep 2017 Amgen and Simcere Pharmaceutical Group agree to co-promote and co-develop four undisclosed biosimilars in China for Inflammation and Cancer
  • 26 Sep 2017 Preclinical trials in Cancer in China (Parenteral)
  • 26 Sep 2017 Preclinical trials in Inflammation in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top